首页> 美国卫生研究院文献>Evidence-based Complementary and Alternative Medicine : eCAM >Discovery of a Novel ERp57 Inhibitor as Antiplatelet Agent from Danshen (Salvia miltiorrhiza)
【2h】

Discovery of a Novel ERp57 Inhibitor as Antiplatelet Agent from Danshen (Salvia miltiorrhiza)

机译:从丹参(丹参)中发现一种新型ERp57抑制剂作为抗血小板药。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Danshen (Salvia miltiorrhiza) is a well-known herb in Traditional Chinese Medicine (TCM) for treating cardiovascular diseases, but the underlying mechanism remains to be fully elucidated. Here, we showed that Danshen and its active ingredient rosmarinic acid exhibited antiplatelet effects through the inhibition of ERp57, a member of protein disulfide isomerase (PDI) with potential roles in platelet aggregation. Danshen extract (DSE) exhibited potent inhibitory effects on the platelet aggregation induced by arachidonic acid- (AA-) induced platelet aggregation and the enzymatic activity of ERp57. Rosmarinic acid was identified by virtual screening and molecular docking as one of the hit compounds for ERp57. In line with this, rosmarinic acid displayed significant inhibitory effect on ERp57 activity and inhibited AA-induced platelet aggregation. Taken together, we demonstrated for the first time that DSE and rosmarinic acid displayed inhibitory effects on the catalytic activity of ERp57, providing evidence of the regulatory role of ERp57 underlying the antiplatelet effects of Danshen.
机译:丹参(Salvia miltiorrhiza)是中药(TCM)中用于治疗心血管疾病的著名草药,但其潜在机理尚待充分阐明。在这里,我们显示丹参及其活性成分迷迭香酸通过抑制ERp57发挥抗血小板作用,ERp57是蛋白二硫键异构酶(PDI)的成员,在血小板聚集中具有潜在作用。丹参提取物(DSE)对花生四烯酸(AA-)诱导的血小板凝集和ERp57的酶活性具有抑制作用。通过虚拟筛选和分子对接将迷迭香酸鉴定为ERp57的热门化合物之一。与此相符,迷迭香酸对ERp57活性显示出显着的抑制作用,并抑制了AA诱导的血小板凝集。两者合计,我们首次证明DSE和迷迭香酸对ERp57的催化活性表现出抑制作用,提供了ERp57在丹参抗血小板作用基础上的调节作用的证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号